Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | KLK7 | P49862 | 4/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1172293 | 0.98 | MEN1 (0.54) | MEN1KMT2AMAPTATMTDP1 | |
| SCHEMBL31323929 | 0.98 | MEN1 (0.54) | MEN1KMT2AMAPTATMTDP1 | |
| SCHEMBL18311726 | 0.98 | MEN1 (0.54) | MEN1KMT2AMAPTATMTDP1 | |
| SCHEMBL9744436 | 0.98 | MEN1 (0.54) | MEN1KMT2AMAPTATMTDP1 | |
| SCHEMBL7886952 | 0.96 | ALDH1A1 (0.49) | MEN1KMT2AMAPTATMTDP1 | |
| SCHEMBL18623243 | 0.92 | ALDH1A1 (0.50) | MEN1KMT2AMAPTATMTDP1 | |
| SCHEMBL24740428 | 0.87 | TDP1 (0.55) | TDP1L3MBTL1ALDH1A1USP2ALOX15 | |
| SCHEMBL5827221 | 0.87 | CYP1A2 (0.48) | MEN1KMT2AMAPTATMTDP1 | |
| SCHEMBL7683870 | 0.87 | CYP1A2 (0.48) | MEN1KMT2AMAPTATMTDP1 | |
| SCHEMBL10073831 | 0.86 | ALDH1A1 (0.46) | MEN1KMT2AMAPTATMTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9822398-B2 | Labelling compounds and their use in assays | ATLAS GENETICS LIMITED (GB) | 2017-11-21 | — | — | US | disclosed |
| CN-105948682-A | Plastic concrete used for preventing leakage, and preparation method thereof | 中国港湾工程有限责任公司 | 2016-09-21 | — | — | CN | disclosed |
| EP-2300478-B1 | 1-HETEROCYCLYL-1,5-DIHYDRO-PYRAZOLO[3,4-D]PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS PDE9A MODULATORS | BOEHRINGER INGELHEIM INT (DE) | 2016-03-23 | — | — | EP | disclosed |
| US-9102679-B2 | Compounds for the treatment of CNS disorders | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-08-11 | — | — | US | disclosed |
| US-9102679-B2 | Compounds for the treatment of CNS disorders | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-08-11 | — | — | US | disclosed |
| US-9096603-B2 | 1-heterocyclyl-1,5-dihydro-pyrazolo[3,4-D] pyrimidin-4-one derivatives and their use as PDE9A modulators | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-08-04 | — | — | US | disclosed |
| US-9096603-B2 | 1-heterocyclyl-1,5-dihydro-pyrazolo[3,4-D] pyrimidin-4-one derivatives and their use as PDE9A modulators | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-08-04 | — | — | US | disclosed |
| US-8962843-B2 | 1,3,4-oxadiazole and 1,3,4-thiadiazole beta-lactamase inhibitors | CUBIST PHARMACEUTICALS, INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-8962844-B2 | 1,3,4-oxadiazole and 1,3,4-thiadiazole β-lactamase inhibitors | CUBIST PHARMACEUTICALS, INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-20150031665-A1 | 1,3,4-OXADIAZOLE AND 1,3,4-THIADIAZOLE BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2015-01-29 | — | — | US | disclosed |
| US-20030087775-A1 | Use of tertiary alcohols or esters as perfuming ingredients | FIRMENICH SA (CH) | 2003-05-08 | — | — | US | disclosed |
| EP-1288280-A2 | Use of tertiary alcohols or esters as perfuming ingredients | FIRMENICH SA (CH) | 2003-03-05 | — | — | EP | disclosed |
| EP-1282611-A1 | SUBSTITUTED PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-02-12 | — | — | EP | disclosed |
| WO-2001085706-A1 | SUBSTITUTED PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-11-15 | — | — | WO | disclosed |
| EP-0713485-B1 | THIOCARBAMOYL COMPOUNDS AS MICROBICIDES | BAYER AG (DE) | 1998-04-15 | — | — | EP | disclosed |
| US-5672617-A | Medicaments containing 1-thiocarbamoyl-5-hydroxy-pyrazoles and their use as agents for combating septic shock | BAYER AKTIENGESELLSCHAFT (DE) | 1997-09-30 | — | — | US | disclosed |
| EP-0713485-A1 | THIOCARBAMOYL COMPOUNDS | BAYER AG (DE) | 1996-05-29 | — | — | EP | disclosed |
| WO-1995004722-A1 | THIOCARBAMOYL COMPOUNDS | BAYER AKTIENGESELLSCHAFT (DE) | 1995-02-16 | — | — | WO | disclosed |
| EP-0115409-A2 | Indane derivatives, their production and use thereof | Takeda Chemical Industries, Ltd. (JP) | 1984-08-08 | — | — | EP | disclosed |
| US-3966792-A | Prostaglandin compounds | ONO PHARMACEUTICAL CO., LTD. (JA) | 1976-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031665-A1 | 1,3,4-OXADIAZOLE AND 1,3,4-THIADIAZOLE BETA-LACTAMASE INHIBITORS | BTD, BLVRB, PEPD | MEN1 3716/4885KMT2A 3510/4885MAPT 3656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.